# The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.

> **NCT03678090** · PHASE2 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- Pleural Effusion
- Cancer, Lung

## Interventions

- **DRUG:** tPA standard dosage
- **DRUG:** tPA low dosage

## Key facts

- **NCT ID:** NCT03678090
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-01
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-02-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Local IRB recommended IND exemption from FDA, study timeline not able to be met.
- **Last updated:** 2020-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03678090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03678090, "The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03678090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*